Abnormally High Levels of Virus-Infected IFN-γ+CCR4+CD4+CD25+ T Cells in a Retrovirus-Associated Neuroinflammatory Disorder
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) is a human retrovirus associated with both HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), which is a chronic neuroinflammatory disease, and adult T-cell leukemia (ATL). The pathogenesis of HAM/TSP is known to be as follows: HTLV-1-infected T cells trigger a hyperimmune response leading to neuroinflammation. However, the HTLV-1-infected T cell subset that plays a major role in the accelerated immune response has not yet been identified. PRINCIPAL FINDINGS: Here, we demonstrate that CD4(+)CD25(+)CCR4(+) T cells are the predominant viral reservoir, and their levels are increased in HAM/TSP patients. While CCR4 is known to be selectively expressed on T helper type 2 (Th2), Th17, and regulatory T (Treg) cells in healthy individuals, we demonstrate that IFN-gamma production is extraordinarily increased and IL-4, IL-10, IL-17, and Foxp3 expression is decreased in the CD4(+)CD25(+)CCR4(+) T cells of HAM/TSP patients as compared to those in healthy individuals, and the alteration in function is specific to this cell subtype. Notably, the frequency of IFN-gamma-producing CD4(+)CD25(+)CCR4(+)Foxp3(-) T cells is dramatically increased in HAM/TSP patients, and this was found to be correlated with disease activity and severity. CONCLUSIONS: We have defined a unique T cell subset--IFN-gamma(+)CCR4(+)CD4(+)CD25(+) T cells--that is abnormally increased and functionally altered in this retrovirus-associated inflammatory disorder of the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mogamulizumab targets CCR4, a chemokine receptor highly expressed by HTLV-1-infected T cells [198,199,200], with phase I and II clinical trials resulting in an overall response rate (ORR) of 50% [201,202,203].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [200]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS
Gessain, A., Vernant, J. C., Maurs, L., Barin, F., Gout, O., Calender, A., & De Thé, G. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92734-5 · Cited by 2,843
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., & Tara, M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91298-5 · Cited by 2,404
Adult T-cell leukemia: clinical and hematologic features of 16 cases
Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., & Uchino, H. (1977) · Blood · doi:10.1182/blood.v50.3.481.481 · Cited by 2,316
Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis
Viglietta, V., Baecher-Allan, C., Weiner, H. L., & Hafler, D. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031579 · Cited by 1,856 · cited 1×
“Previous studies have observed significant reductions in Foxp3 expression and/or Treg function in several human autoimmune diseases, including multiple sclerosis (MS), myasthenia gravis, and type I diabetes [17,19], suggesting that defects in Foxp3 expression and/or Treg function may precipitate the loss of immunologi…”
ResultSurface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828 · cited 3×
“More recently, it has been observed that CCR4 is expressed on Th17 cells [23].”
BackgroundShimoyama, M., & members of The Lymphoma Study Group (1984–87) (1991) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08051.x · Cited by 1,608 · cited 1×
“HAM/TSP was diagnosed according to the guidelines defined by the WHO, and ATL was diagnosed on the basis of the criteria proposed by Shimoyama [46].”
MethodFoxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease
Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z., Shimizu, J., Takahashi, T., & Nomura, T. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00427.x · Cited by 1,555 · cited 4×
“Although Treg cells are phenotypically similar to activated T cells, they can be identified ex vivo by the intracellular expression of the transcriptional regulator Foxp3 [18], which is critical for the development and function of Treg cells in both mice and humans [17].”
BackgroundResultInfluentialFOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT
Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., Bates, D. L., Guo, L., Han, A., Ziegler, S. F., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.042 · Cited by 1,189 · cited 1×
“The high Foxp3 expression without cytokine production and low Foxp3 expression with cytokine production in CD4CD25CCR4 T cells (Figure 3A) are consistent with recent reports demonstrating that Foxp3 can target and repress the transcriptional activity of NFAT-AP-1 complexes present at the cytokine promoter [43].”
Result
Cited by
Items 101–140 of 140
Perfil de citocinas na patogênese da infecção do vírus Linfotrópico de células T humanas HTLV-1
Padilha, M. D. M., Viana, V. B. D. J., Balcázar, O. D. A., Balcázar, A. F. A., Albito, G. A. A., da Costa, A. J. M., Balcazar, M. D. C. A., & Feitosa, R. N. M. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n4-029 · Cited by 1
IMMUNOPATHOGENESIS OF HTLV-I-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS
Santos, S. B., Muniz, A. L., Carvalho, E. M., & Santos, E. (2009) · Cited by 1
Human Adult T-Cell Leukemia Virus Type 1 (HTLV1)
Jetly, S., Singh, S., Khatri, M., Banswal, S., & Pandey, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4480-0_27 · Cited by 1
Lima, A. C. M. M., Silva, D. I. B. D. S., Campos, R. F., Andrade, F. D. O., Nascimento, J. O. D. S., Santana, C. S., Barreto, L. N., Cucco, M. S., Borba, M. M. N., Costa, D. T., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29912 · Cited by 1
“42 The HBZ protein interferes with the NF ‐ κ B pathway 43 and enhances CCR4 expression 44 which is a chemokine receptor highly expressed in HAM/TSP. 45 In animal models, HBZ protein seems to affect the function of Forkhead box P3 protein (FOXp3).”
InfluentialYamano, Y. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3677 · Cited by 1
Self-citationAssone, T., Menezes, S. M., Gonçalves, F. D. T., Folgosi, V. Â., Prates, G. D. S., Dierckx, T., Braz, M., Smid, J., Haziot, M. E., Marcusso, R. M. N., et al. (2021) · medRxiv · doi:10.1101/2021.03.16.21253707 · Cited by 1
“In contrast to IL-17A, exacerbated IFN-γ production (ex vivo and in vitro) has been demonstrated by several groups, including ours, as a hallmark of HAM/TSP[20,2225].”
BackgroundSato, T., Araya, N., Yagishita, N., Ando, H., & Yamano, Y. (2011) · InTech eBooks · doi:10.5772/23265
“This is known to induce a variety of abnormalities, such as proliferation, cellular activation, and proinflammatory changes (Boxus et al., 2009; Satou et al., 2010; Yamano et al. 2009).”
InfluentialSelf-citationYamano, Y. (2015) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12256
“While there are many chronic inflammatory disorders for which the initiating trigger is unknown, human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare neurodegen- erative chronic inflammatory disease clearly caused by HTLV-1.”
BackgroundResultInfluentialSelf-citationCD64 as a biomarker and therapeutic target in HAM/TSP and HTLV-1-associated Infective Dermatitis
Khouri, R., Soares, G., Silva-Santos, G., Santana, G., Thepen, T., Farré, L., Bittencourt, A., López, G., Talledo, M., Gotuzzo, E., et al. (2011) · Retrovirology · doi:10.1186/1742-4690-8-s1-a95
“Previous studies have linked CD8+ T cell subset IFNgamma production to HAM/TSP disease evolution [1,2], as well as its dependence on infected monocytes (EnoseAkahata et al.”
BackgroundYamano, Y., & Jacobson, S. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7219-4_12
Self-citationMenezes, S. M., Decanine, D., Brassat, D., Khouri, R., Schnitman, S. V., Kruschewsky, R. D. A., López, G., Álvarez, C., Talledo, M., Gotuzzo, E., et al. (2014)
Semeão, L. E. D. S. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2015.tde-20052015-115430
“Trabalhos têm demonstrado que pouco é alterada a produção de IL-5 e IL-10 (45), embora outros mostram decréscimo na produção de IL-10 (44) e IL-17 (42-44) dados que em conjunto apoiam para um fenótipo voltado a Th1, e não Th17 como observado em outras doenças neurológicas como a”
BackgroundInfluentialThe Pathogenesis of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
Rowan, A. G., & Bangham, C. R. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-33189-8_1
Neuroimmunomodulation of Human T-Lymphotrophic Virus Type I/II Infection
Yamano, A., Yamano, Y., & Jacobson, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_28
Self-citationSato, T., & Yamano, Y. (2018) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12467
Self-citationVI. Diagnosis and Treatment of HTLV-1 Associated Myelopathy (HAM)
Yamano, Y. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.1404
Self-citation山野嘉久 (2020) · doi:10.34397/jsnd.25.1_87
Gallo, R. C. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727215751.793556715
Cannabinoid receptors as new targets for HTLV-1 associated myelopathy (HAM/TSP) treatment
Fadaee, A., Mohammadi, F. S., Ariaee, N., Ghezeldasht, S. A., Valizadeh, N., Kheradmand, F., Boostani, R., Rafatpanah, H., & Rezaee, S. A. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.105659
Kimura, M., Umekita, K., Iwao, C., Kawano, K., Hashikura, Y., Hashiba, Y., Hidaka, T., Sugata, K., Satou, Y., & Miyazaki, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1480506
Adverse Lipid Profiles and Increased Cardiovascular Risks in People with HAM/TSP
Novaes, A. F., Ferreira, Q. R., Nascimento, J. O. D. S., Silva, R. M. L., Moura, M. N., da Cruz, A. L. B., Fernandes, L. A., Umeda, A. S., Santos, J. P. D. M. D. F., Mota-Miranda, A. C. A., et al. (2025) · AIDS Research and Human Retroviruses · doi:10.1177/08892229251365946
Gois, L. L., Soares, B. N. R. R., Regis-Silva, C. G., Zanette, D. L., Lisboa, R., Nascimento, R. S., Coutinho Junior, R., Galvão-Castro, B., & Grassi, M. F. R. (2024) · Figshare · doi:10.6084/m9.figshare.26129756
Assone, T., Menezes, S. M., de Toledo Gonçalves, F., Folgosi, V. Â., da Silva Prates, G., Dierckx, T., Braz, M., Smid, J., Haziot, M. E., Marcusso, R. M. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26551930
Type 1 leprosy reaction in a patient coinfected with HTLV-1 and Mycobacterium leprae
Faria, L. G. A. P., Moura, M. N., da Cruz, A. L. B., Andrade, F. D. O., Cerqueira, A. P. N., Cariús, L. F., Novaes, A. F., Ribeiro, S. O., Takenami, I., Barreto, F. K., et al. (2025) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2025.12.001
Ferreira, A. P., Magalhães, P. M. R., Belmont, T. F. D. M., de Morais, C. N. L., Vasconcelos, L. R. S., de Moura, P. M. M. F., & Rocha‐Filho, P. A. S. (2026) · Journal of Medical Virology · doi:10.1002/jmv.70839
Unmasking HAM/TSP: understanding HTLV-1-driven neurological disease
Letafati, A., Tajik, S., Rad, M. V., Shahbahrami, R., Moulaeian, M., Norouzi, M., & Mozhgani, S. (2026) · Journal of NeuroVirology · doi:10.1007/s13365-026-01305-x · Cited by 1
“…role in the development of HTLV-1 infection and HAM/TSP. Studies have shown that a high proviral load (PVL) is associated with HAM/TSP and other HTLV-1-associated diseases such as peripheral HTLV-1 and exhibit a high frequency of HTLV-1 tax mRNA compared to CD4 + CD25-cells (Yamano et al. 2009).”
Impact of oncogenic viruses on autoimmune diseases and tumorigenesis
Sofiani, V. H., Mahani, F. K., Farsiu, N., Yousefi, M., Naderi, M., Ahmadi, G., & Nakhaie, M. (2026) · Infectious Agents and Cancer · doi:10.1186/s13027-026-00746-7 · Cited by 1
“The authors further demonstrated that the frequency of CD4 + CD25+FOXP3 − T cells was significantly elevated in these patients and was associated with the clinical severity of HAM/TSP [127].”
Effet du valproate sur l'expression du génome viral dans les cellules infectées par HTLV-1
Belrose, G. (2011) · theses.fr (ABES) · doi:10.70675/39a69ddez13c8z43b6z910dz5aba75f31d16
Réplication du virus HTLV-1 et phénotype lymphocytaire : implication dans l’apoptose
Zane, L. K. (2009) · theses.fr (ABES) · doi:10.70675/fd539132zb083z4790za609z1429c33d99c7
Nakajima, S., Hino, M., Takenouchi, N., Yamano, Y., Yamagishi, M., Odaka, T., Admadiani, F. R., Faye, C., Uchimaru, K., Fujisawa, J., et al. (2026) · Pathogens · doi:10.3390/pathogens15040450
Self-citationWeterings, D. A., Yee, L. L. C., Watber, P., Baylon, J., Greiller, C. L., Taylor, G. P., Cook, L. B. M., & Rowan, A. G. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100235
Nakamura, T., & Satoh, K. (2026) · Pathogens · doi:10.3390/pathogens15050555
Human T-cell leukaemia virus type 1 : parasitism and pathogenesis
松岡, 雅., Bangham, C. R. M., & Matsuoka, M. (2017) · Institutional Repositories DataBase (IRDB)
The HTLV-1 HBZ Oncoprotein and Its Role in Adult T-Cell Leukemia/Lymphoma
Accolla, R. S., Shallak, M., & Forlani, G. (2026) · Cancers · doi:10.3390/cancers18132101
Immunophenotype and proviral landscape of HTLV-1c infection and pulmonary disease
Hirons, A., Jansz, N., Khoury, G., Ellenberg, P. C., Collins, S., Cooney, J. P., Zaunders, J., Williams, L., Nair, K. N., Yap, A. H. Y., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106403 · Cited by 1
“33,34 Given the clinical significance of HAPD in subtype-C infection in Central Australia, we first characterised CD4 + T-cells associated with lung homing (T LH , CCR4 + CD49d + Integrin β 7 − ).”
Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions – A Narrative Review
Rezaei, M. M., Nia, M. K., Rouzbahani, K. A., Kazemi, M., Hosori, N. A., Norouzi, M., Sotoudegan, F., Eslami, N., Ariamand, N., Shahnavaz, V., et al. (2026) · Health Science Reports · doi:10.1002/hsr2.72863
“However, IL‐ 10 treatment was associated with a side effect of thrombocytopenia [63, 64].”
Metadata
- Authors
- Yamano, Y., Araya, N., Sato, T., Utsunomiya, A., Azakami, K., Hasegawa, D., Izumi, T., Fujita, H., Aratani, S., Yagishita, N., Fujii, R., Nishioka, K., Jacobson, S., & Nakajima, T.
- Affiliations
- St. Marianna University School of Medicine (JP)
- Imamura Hospital (JP)
- National Institutes of Health (US)
- Corresponding author
- Yamano, Yoshihisa
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-08-05
- Volume
- 4
- Issue
- 8
- Pages
- e6517
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2715877
- OpenAlex
- W2123524329
- Cited by
- 140
- References
- 48
- Citations by year
- 2026: 10 · 2025: 5 · 2024: 12 · 2023: 6 · 2022: 7 · 2021: 6 · 2020: 8 · 2019: 9 · 2018: 6 · 2017: 9 · 2016: 10 · 2015: 11 · 2014: 10 · 2013: 11 · 2012: 7
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Uehara Memorial Foundation
- Ministry of Education, Culture, Sports, Science and Technology
- National Institute of Biomedical Innovation
- Mishima Kaiun Memorial Foundation
- Japan Society for the Promotion of Science (20249052)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- HTLV-1, HAM/TSP, adult T-cell leukemia/lymphoma, CCR4, CD4+CD25+ T cells, regulatory T cells, Foxp3, interferon-gamma, neuroinflammation, viral reservoir, Th17 cells, Th2 cells, IL-17, IL-10, IL-4, disease activity
- MeSH terms
- Interferon-gamma, Nervous System Diseases, T-Lymphocytes, Human T-lymphotropic virus 1, HTLV-I Infections, CD4 Antigens, Interleukin-4, Case-Control Studies, Interleukin-10, Cell Proliferation, Interleukin-2 Receptor alpha Subunit, Receptors, CCR4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.